PX-12

DB05448InvestigationalSmall molecule

PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits tumor growth in animal models. Since high... Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced metastatic cancer.

Mechanism: PX-12 irreversibly inhibits the redox protein thioredoxin, which has been associated with cancer and tumor growth.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, and pancreatic cancer.Curator reviewed
Formula / weight: C₇H₁₂N₂S₂ · 188.314 g/mol (avg)
Code names: PX-12

Resolves to

Compound

UNII8PQ9CZ8BTJCAS141400-58-0ChEMBLCHEMBL406050ChEBI94291PubChem219104

Structure

InChIKeyBPBPYQWMFCTCNG-UHFFFAOYSA-NSMILESCCC(C)SSC1=NC=CN1

Targets

Q16881TXNRD1P10599TXN

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

17+ReferencesStructured and connected to the statements they support

Which drugs share a target with PX-12, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account